Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-masked, Multicenter, Parallel Group, Phase 3 Clinical Trial to Compare the Efficacy and Safety of JL14002 Monoclonal Antibody Injection Versus Ranibizumab Injection in Patients With Neovascular (Wet) Age-Related Macular Degeneration (wAMD)

NCT07389577 is registered in ClinicalTrials.gov with Jecho Biopharmaceuticals Co., Ltd. as lead sponsor.

NCT NCT07389577
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07389577 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-masked, Multicenter, Parallel Group, Phase 3 Clinical Trial to Compare the Efficacy and Safety of JL14002 Monoclonal Antibody Injection Versus Ranibizumab Injection in Patients With Neovascular (Wet) Age-Related Macular Degeneration (wAMD)
Lead sponsor
Jecho Biopharmaceuticals Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
March 1, 2022
Completion date
September 23, 2024
Enrollment
443 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

wet age-related macular degeneration